Current progress and limitations of research regarding the therapeutic use of adipose-derived stem cells: literature review

Abstract

Background Adipose tissue has recently become one of the most promising and predominant sources of mesenchymal stem cells owing to its high accessibility, culturing properties, regenerative potential, and relatively fewer ethical considerations. From the time of the adipose-derived stem cells (ADSCs) discovery, many beneficial properties have been found, including their regenerative, anti-inflammatory, immunomodulatory, and antimicrobial effects. The number of publications and clinical trials using ADSCs has increased significantly worldwide, attesting to the promising nature of the therapeutic properties of ADSCs. Main body of the abstract In clinical studies, ADSCs are mainly used to treat wounds, multiple sclerosis, soft tissue trauma, aging, diabetes, Parkinson’s disease, bone and cartilage regeneration, strokes, and spinal cord injuries. Few and insignificant adverse effects after ADSC treatment have been documented, suggesting their relative safety for clinical use. Despite significant progress in ADSC-related studies, several issues are yet to be addressed, including a lack of standardization of ADSC-associated protocols and the methods used to obtain them, inconsistent dosages, small numbers of patients in each treatment group, and variable graft purity. This severely complicates our ability to compare these studies, making the results even of similar studies controversial. Short conclusion This review described the current stage of ADSCs-based treatment outcomes and their limitations, associated with standardization of ADSCs.